EASL International Liver Congress 2018
April 11-15, 2018
ENYO Pharma is proud to announce that its Poster has been selected to be presented at EASL International Liver Congress in Paris on April 11-15th. The company team will present its latest Hepatitis B studies and data about its EYP001 compound (FXR agonist) developed for chronic hepatitis B patients. The annual Congress, which aim at presenting the latest topics in liver research, will be a great opportunity for the company as more than 10,000 delegates and 250 media representatives from all over the world will participate.